<bill session="106" type="h" number="5235" updated="2013-07-14T18:55:10-04:00">
  <state datetime="2000-09-20">REFERRED</state>
  <status>
    <introduced datetime="2000-09-20"/>
  </status>
  <introduced datetime="2000-09-20"/>
  <titles>
    <title as="introduced" type="short">Prescription Drug Competition Act of 2000</title>
    <title as="introduced" type="official">To ensure the timely availability of generic drugs through enhancement of drug approval and antitrust laws enforced by the Food and Drug Administration and the Federal Trade Commission regarding brand name drugs and generic drugs.</title>
  </titles>
  <sponsor id="400425"/>
  <cosponsors>
    <cosponsor id="400026" joined="2000-09-20"/>
    <cosponsor id="400050" joined="2000-09-20"/>
    <cosponsor id="400576" joined="2000-09-20"/>
    <cosponsor id="400106" joined="2000-09-20"/>
    <cosponsor id="400387" joined="2000-09-20"/>
  </cosponsors>
  <actions>
    <action datetime="2000-09-20">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR E1538"/>
    </action>
    <action state="REFERRED" datetime="2000-09-20">
      <text>Referred to the Committee on Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2000-09-20">
      <text>Referred to House Commerce</text>
    </action>
    <action datetime="2000-09-20">
      <text>Referred to House Judiciary</text>
    </action>
    <action datetime="2000-10-20">
      <text>Referred to the Subcommittee on Health and Environment.</text>
      <committee name="House Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF04" subcommittee="Health and Environment" name="House Commerce"/>
    <committee code="HSJU" name="House Judiciary" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Actions and defenses"/>
    <term name="Commerce"/>
    <term name="Contracts"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Fines (Penalties)"/>
    <term name="Generic drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Injunctions"/>
    <term name="Law"/>
    <term name="Prescription pricing"/>
    <term name="Restrictive trade practices"/>
  </subjects>
  <amendments/>
  <summary>9/20/2000--Introduced.
Prescription Drug Competition Act of 2000 - Requires a brand name drug company and a generic drug applicant that enter into an agreement regarding the sale or manufacture of a generic drug determined or likely to be the therapeutic equivalent of such brand name drug, when such agreement could limit the research, development, manufacture, marketing, or sale of such generic drug, to file with the Federal Trade Commission and the Secretary of Health and Human Services the text of such agreement and an explanation of whether such agreement could delay, restrain, limit, or otherwise interfere with the production, manufacture, or sale of the generic drug in question. Requires such filing within ten days of agreement execution. Provides civil penalties for violation.</summary>
</bill>
